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Alström Syndrome (ALMS) is an ultra-rare multisystem genetic disorder caused by autosomal recessive variants in
the ALMS1 gene, which is located on chromosome 2p13. ALMS is a multisystem, progressive disease characterised
by visual disturbance, hearing impairment, cardiomyopathy, childhood obesity, extreme insulin resistance,
accelerated non-alcoholic fatty liver disease (NAFLD), renal dysfunction, respiratory disease, endocrine and urologic
disorders. Clinical symptoms first appear in infancy with great variability in age of onset and severity. ALMS has an
estimated incidence of 1 case per 1,000,000 live births and ethnically or geographically isolated populations have a
higher-than-average frequency. The rarity and complexity of the syndrome and the lack of expertise can lead to
delayed diagnosis, misdiagnosis and inadequate care. Multidisciplinary and multiprofessional teams of experts are
essential for the management of patients with ALMS, as early diagnosis and intervention can slow the progression
of multi-organ dysfunctions and improve patient quality of life.
These guidelines are intended to define standard of care for patients suspected or diagnosed with ALMS of any
age. All information contained in this document has originated from a systematic review of the literature and the
experiences of the authors in their care of patients with ALMS. The Appraisal of Guidelines for Research &
Evaluation (AGREE II) system was adopted for the development of the guidelines and for defining the related levels
of evidence and strengths of recommendations.
These guidelines are addressed to: a) specialist centres, other hospital-based medical teams and staffs involved with
the care of ALMS patients, b) family physicians and other primary caregivers and c) patients and their families.
Keywords: Alström syndrome, Guidelines, Rare disease, Blindness, Deafness, Cardiomyopathy, Insulin resistance,
Obesity, Non-alcoholic fatty liver disease© The Author(s). 2020 Open Access This artic
which permits use, sharing, adaptation, distrib
appropriate credit to the original author(s) and
changes were made. The images or other thir
licence, unless indicated otherwise in a credit
licence and your intended use is not permitte
permission directly from the copyright holder
The Creative Commons Public Domain Dedica
data made available in this article, unless othe
* Correspondence: Tarekegn.Geberhiwot@uhb.nhs.uk
1Department of Diabetes, Endocrinology and Metabolism, University
Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital,
Birmingham B15 2TH, UK
20Institute of Metabolism and System Research, University of Birmingham,
Birmingham, UK
Full list of author information is available at the end of the articlele is licensed under a Creative Commons Attribution 4.0 International License,
ution and reproduction in any medium or format, as long as you give
the source, provide a link to the Creative Commons licence, and indicate if
d party material in this article are included in the article's Creative Commons
line to the material. If material is not included in the article's Creative Commons
d by statutory regulation or exceeds the permitted use, you will need to obtain
. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
tion waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
rwise stated in a credit line to the data.
Tahani et al. Orphanet Journal of Rare Diseases          (2020) 15:253 Page 2 of 22Background
Alström Syndrome (ALMS; OMIM #203800) is an ultra-
rare multisystem genetic disorder caused by pathogenic
variants of ALMS1 gene. This syndrome was first de-
scribed by Carl-Henry Alström in 1959 as a progressive
retinal degeneration, obesity, neuronal hearing loss and
insulin resistance [1]. Clinical features, time of onset and
severity can vary greatly among and even within families
bearing identical genetic alterations. The disease is re-
lentlessly progressive in nature which can result in pre-
mature death.
The rarity of this disorder, the complexity of the syn-
drome and the scarcity of expertise can translate into
misdiagnosis, delayed diagnosis, and barriers to adequate
care. This results in inadequate or inappropriate treat-
ment, loss of confidence in the healthcare system, and
patient disempowerment. To date, there is no disease
specific therapy for ALMS and the mainstay of manage-
ment involves multidisciplinary and multiprofessional
teams of experts as early diagnosis and intervention can
slow the progression of multi-organ dysfunctions and
improve the longevity and quality of life of patients.
There are no national or international management
guidelines/ standard operating procedures to guide how
best to care for patients with ALMS. The European
Alström Syndrome society (ASEU) (www.alstromeurope.
org) has initiated the development of a comprehensive
disease management guideline to provide a resource for
the multidisciplinary team, and to support patients, care-
givers and their primary care professionals on the
current diagnosis, treatment, monitoring and outcome
measures for patients with ALMS. This document repre-
sents general guidelines, which in the opinion of the au-
thors can inform care providers about the needs of
patients with ALMS in order to provide equitable and
improved care. It defines standard of care for ALMS pa-
tients, fosters shared care arrangements between expert
centres and family physicians, and empowers patients.
The guidelines refer to the management of patients sus-
pected or diagnosed with ALMS of any age. These
guidelines should be of value to: a) specialist centres,
other hospital-based medical teams and other staffs in-
volved with the care of ALMS patients, b) family physi-
cians and other primary caregivers and c) patients and
their families.
Methods
These guidelines have been developed by International
expert physicians, geneticists, allied healthcare profes-
sionals and patient support groups with a common aim
to support equitable care by standardising the standard
of care for all patients with ALMS. The Guidelines De-
velopment Group (GDG) consisted of expert representa-
tives from a range of professional groups includingpaediatric and adult endocrinologists, metabolic spe-
cialists, cardiologists, ophthalmologists, Ear, Nose
and Throat (ENT) specialists, respiratory specialists,
pathologists, geneticists, basic scientists, specialist
metabolic dieticians, physiotherapists, psychologists,
specialist nurses and patient support group represen-
tatives. The GDG Committee agreed the remit of the
guidelines and selected a list of guidelines topics for
development.
A systematic literature review on ALMS of the last
45 years until October 2019 was carried out using
Medline, MedLink, Embase and the Cochrane Library.
Relevant published papers considered by the GDG
members as important were included. The initial search
identified 220 reference abstracts, of which 179 were
accepted as relevant after the first screen. References
related to a single topic were pulled together and the
GDG was divided into subgroups aimed to critically ap-
praise references devoted to a specific topic (Genetics
and Diagnosis, Hearing and Sight, Cardio-respiratory
system, Endocrine and Metabolism, Gastro-intestinal
and Genito-urinary tract, Psychosocial aspects, and
overall management and follow up). The committee
discussed by teleconference in August 2019 and met in
October 2019 in Birmingham, UK. They also corre-
sponded by email on a regular basis throughout the
duration of the guidelines development. During the
workshop, the GDG adopted the second version of the
Appraisal of Guidelines for Research & Evaluation
(AGREE II) system as methodological reference in
order to meet the guideline development standards.
Relevant papers were evaluated by members of the
GDG before the evidence was considered. Section
leaders individually assessed the literature and wrote a
short document describing the study findings and re-
lated recommendations. All GDG members discussed
the draft documents. Evidence levels were classified in
accordance with the Grading of Recommendations,
Assessment, Development and Evaluations (GRADE)
methodology and level of evidence were graded from A
to C (Table 1). In addition, for the adoption of recom-
mendations, we formed a panel of experts representa-
tive of the specialists caring for ALMS patients and
used the Delphi method for the development of our guide-
lines. The guidelines will be published in an open access
journal and made freely accessible through the ALMS so-
ciety website. These guidelines will be revised every 3–5
years to reflect new data pertaining to future research
findings, new therapies and the development of diagnostic
methods. The development of these guidelines was made
without external financial support from industries in-
volved in the manufacturing of therapies for ALMS. Com-
peting interests of members of the guideline development
group have been recorded in writing and addressed.
Table 1 Evidence levels and strength of recommendations
Item Definition
Level of evidence
A. High-quality evidence Further research is unlikely to change our confidence in the estimate of effect. Consistent evidence
from the Randomised Controlled Trials (RCTs) without important limitations or exceptionally strong
evidence from observational studies.
B. Moderate-quality evidence Further research is likely to have an important impact on our confidence in the estimate of effect
and may change the estimate. Evidence from RCTs with important limitations (inconsistent results,
methodologic flaws, indirect or imprecise), or very strong evidence from observational studies.
C. Low-quality evidence Further research is very likely to have an important impact on our confidence in the estimate of
effect and is likely to change the estimate. Evidence for at least one critical outcome from
observational studies, case series, or from RCTs with serious flaws, or indirect evidence, or expert’s
consensus.
Strength of recommendation
1. Strong recommendation Recommendation can apply to most patients in most circumstances.
2. Weak recommendation The best course of action may differ depending on circumstances or patient or society values.
Other alternatives may be equally reasonable.
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How do you define Alström syndrome (ALMS)?
Statement # 1: ALMS is a progressive and multi-
systemic disorder caused by autosomal recessive variants
in the ALMS1 gene. The disease is characterized by vis-
ual and hearing impairments, cardiomyopathy, renal
dysfunction, extreme insulin resistance (IR) and its re-
lated complications. Clinical symptoms first appear in
infancy with great variability in age of onset and severity.
 Level of evidence: A
 Strength of recommendation: 1
 Experts’ opinion: completely agree (88%), mostly
agree (12%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%)
How common is ALMS?
Statement # 2: Alström syndrome is a pan-ethnic ultra-
rare condition, with an estimated incidence of 1 case per
1,000,000 live births. Ethnically or geographically isolated
populations have a higher-than-average frequency of
ALMS.
 Level of evidence: C
 Strength of recommendation: 2
 Experts’ opinion: completely agree (75%), mostly
agree (19%), partially agree (6%), mostly disagree
(0%) and completely disagree (0%)
The prevalence of ALMS is difficult to estimate as
some individuals with attenuated forms of this syndrome
may be underdiagnosed [2]. There is a higher frequency
of some specific ALMS1 pathogenic variants in certain
ethnic populations, for example, c.10534_10535ins in
French Acadians, and c.10775delC in up to 20% of pa-
tients of English descent [3, 4]. Based on our collectivenational Alström service experience in Europe there are
at least 263 cases known to us including 89 in the UK,
64 in France, 60 in Turkey, 39 in Italy and 15 in Spain.
Molecular and genetic basis of the disease
Statement # 3: ALMS is a monogenic disorder caused by
homozygous or compound heterozygous variants in the
ALMS1 gene, which is located on chromosome 2p13. Of
the 268 pathogenic variants identified so far, 96% are
nonsense or frameshift changes (insertions and deletions).
 Level of evidence: A
 Strength of recommendation: 1
 Experts’ opinion: completely agree (81%), mostly
agree (19%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%).
The syndrome was first described by Carl Henry
Alström in 1959 in three cousins [1]. Goldstein &
Fialkow, in 1973 [5], described a new Alström family
and reviewed the clinical phenotype of the three families
described until then. They proposed an autosomal reces-
sive pattern of inheritance. ALMS1 gene is located on
chromosome 2 (region 2p13.1) [6–8] and contains 23
coding exons [4, 9] that comprises 224 kilobase (kb).
The ALMS1 protein is of unknown function, is widely
expressed in human and mouse tissues [4, 9, 10], and lo-
calizes to centrosomes and the base of cilia [11]. To
date, over 268 pathogenic variants have been involved in
ALMS [4, 9, 12–15] of which 96% are nonsense or
frameshift changes (insertions and deletions) that could
produce truncated, non-functional proteins if translated
[14]. In addition, splice-site mutations [16], deletions
[17], one Alu transposon insertion [18] and one balance
translocation [9] have been described. Among the 24
missense variants in the ALMS1 database, 11 (45.8%) are
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genic, four (16.7%) are benign or likely benign, and five
(21%) are variants of uncertain significance [15]. Taking
into account the different cohorts reported, most of
deleterious variants are clustered in exons 8 (6.1 kb), 10
(1.9 kb) and 16 (1.2 kb), which are considered mutational
hotspots as they comprise 85–97% of the total muta-
tional load for ALMS1 [14, 19].
Clinical presentation
What are the principal manifestations raising the
suspicion of ALMS?
Statement # 4: ALMS is a multisystem, progressive dis-
ease characterised by visual disturbance, hearing im-
pairment, cardiomyopathy, childhood obesity, extreme
insulin resistance, accelerated non-alcoholic fatty liver
disease (NAFLD), renal dysfunction, respiratory dis-
ease, endocrine and urologic disorders. First symptoms
usually occur during the first year of life either with
visual disturbance and/or heart failure and clinical
findings evolve as affected individuals age.
 Level of evidence: A
 Strength of recommendation: 1
 Experts’ opinion: completely agree (94%), mostly
agree (6%), partially agree (0%), mostly disagree (0%)
and completely disagree (0%)
Eyesight and hearing
Visual impairment
Statement # 5: Retinal dystrophy is a major and consist-
ent manifestation (incidence 100%) of the disease leading
to visual impairment that is often severe and can lead to
blindness before the age of 20. Visual impairment is often
one of the first symptoms or even the very first noticeable
manifestation appearing between a few weeks and 6
months of age.
 Level of evidence: A
 Strength of recommendation: 1
 Experts’ opinion: completely agree (88%), mostly
agree (12%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%)
Patients typically present with early onset retinal dys-
trophy due to the degeneration of photoreceptor cells
(cones and rods). At birth, patients do not usually have
manifestations, but within a few weeks signs of visual
impairment occur. The parents usually observe nystag-
mus (“wobbling eyes”), early onset photophobia (avoid-
ance of light) and very poor visual contact. Visual
symptoms occur early in the first months but some cases
are later in onset with a slower evolution [20, 21]. Thefirst referral to an ophthalmologist occurs usually before
the age of one. The rate of visual loss is severe from the
outset and yearly examination will show rapid deterior-
ation. The visual impairment is often profound and
reaches legal blindness most often during the first dec-
ade with teenagers and young adults registered as blind
and, almost all patients having lost vision before the sec-
ond decade.
Statement # 6: Ophthalmic investigations are neces-
sary to evaluate the progressive visual consequences and
support the diagnosis. The initial assessment will include
standard ophthalmic evaluation followed by retinal im-
aging and functional testing (performed according to the
age of patient and level of participation).
 Level of evidence: A
 Strength of recommendation: 1
 Experts’ opinion: completely agree (93%), mostly
agree (7%), partially agree (0%), mostly disagree (0%)
and completely disagree (0%)
The diagnosis of retinal dystrophy is based on the clin-
ical presentation, visual functional evaluation and ocular
imaging. The standard evaluation will define the visual
state of the child according to the age of the child,
categorize the oculomotor presentation (horizontal and/
or pendular nystagmus; strabismus with often exotropia),
evaluate the refraction (usually under routine cycloplegia
with drops that inhibits accommodation to measure ac-
curately the power of glasses), and perform indirect oph-
thalmoscope to visualize the fundus. Main tests to assess
visual impairment in ALMS are summarised in Table 2.
Deafness
Statement # 7: Hearing impairment is the second most
common manifestation of ALMS and characterised by
progressive bilateral sensorineural hearing loss. No ab-
normality is detected during new born screening, but
deafness has been diagnosed as early as the age of 1 and
70% before the age of 10 with lifetime risk of 100%.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (63%), mostly
agree (37%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%)Hearing problems are common manifestations of
ALMS that appear during the course of the disease,
often during childhood, as a progressive sensorineural
deafness. High frequency ranges are the first affected in
both ears. ENT assessment including otologic examin-
ation and audiological evaluation of both ears is neces-
sary to confirm the diagnosis and support the patient.
Table 2 Main tests for visual assessment in ALMS
Refraction status (mandatory) It often shows a hyperopia (ranging from + 3.5 up to + 12) and astigmatism. Myopia is not common.
Full corrective glasses must be prescribed as long as some vision is still present.
Visual acuity (mandatory) Visual acuity is often very low early on (less than 1/10 with Decimal test or 6/60 with 6 m Snellen test)
evolving to residual light perception around the age of 10. However, some cases have shown a later
and milder onset with higher values of vision.
Slit lamp examination (mandatory) The fundus examination varies according to age and among individuals independently from the genetic
status or the extra ocular status. Chronologically the fundus examination can reveal: near normal
appearance, attenuated vessels, hypo-pigmented appearance to the retina with increased visibility of the
choroidal vessels, macula pigmentary changes, pale optic discs and /or papillary drüsen often observed.
Later global pigment mottling and local clumps can appear whereas classical “bone spicules” are seldom
reported. Crystalline deposits have been observed [21].
Electroretinography (ERG)
(mandatory)
The usual characterization is an early onset severe cone-rod dystrophy and confirmation must be made
by a full-field ERG. ERG shows very early and usually profound alteration of the light adapted photopic
responses due to severe alteration of the cones. The follow up highlights a rapid evolution with
diminishing dark-adapted rod responses. Before the end of the first decade, the ERG become un
recordable and shows extinguished cone and rod responses (absent responses using any type of stimuli).
Goldman visual field (Optional) Goldman or Humphrey Visual fields are often unrecordable. Exceptionally more or less pronounced visual
field constriction have been reported and even very exceptionally with some preservation [20, 21].
Optic Coherence Tomography (OCT)
(optional)
The OCT findings are scarcely reported [21–24], because the recording is difficult to achieve especially
in young children with nystagmus, photophobia and need for sedation. Thinning of the macula and
immature retina with persistence of the foveal inner retinal layer were reported [22, 23] but this was
challenged by further reports that showed mild central macular changes in the first decade followed by
loss of photoreceptors and pigment epithelium that correlated with the low vision [21, 24]. The OCT
images in adults show general atrophy of both inner and outer retinal layers. Thinning of the outer
nuclear layer and the outer plexiform layer outside the fovea is a constant finding [21].
Fundus Auto Fluorescence (FAF)
(optional)
FAF is seldom reported with hyper autofluorescent parafoveal ring in two patients and small areas of
hypo and hyperfluorescent zones outside or inside the arcades [21].
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crimination and normal auditory brain stem responses
points to a cochlear origin [25–31]. The pathogenesis is
thought to be due to the alteration of outer hair cells of
the cochlea that occurs after birth [32, 33]. In addition
to the neurosensorial dysfunction, a conductive compo-
nent can occur. The average age of progression of hear-
ing loss is 10-15db/decade [33].
Cardiovascular disease
How do patients with ALMS present with
cardiovascular disease?
Statement # 8: Almost two-thirds of individuals with
ALMS develop congestive heart failure (CHF) at some
stage in their lives, as a result of infantile, juvenile or
adult onset cardiomyopathy. Approximately 40% infants
with ALMS suffer from a transient, severe cardiomyop-
athy between 3 weeks and 4months of age. In those who
survive, there is a risk of recurrence and in those without
infantile cardiomyopathy, de novo disease develops in
approximately 1 out of 5 patients.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (67%), mostly
agree (33%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%)Onset, progression and outcome of cardiomyopathy in
ALMS is variable. The first clinical presentation of the
syndrome is either with nystagmus or infantile onset
cardiomyopathy in 42% within the first 4 months of life
[25]. In the absence of routine genetic testing of those
presenting with infantile cardiomyopathy, diagnosis is
likely to be under-estimated due to premature mortality
in a significant proportion. Of those who recover, ap-
proximately 1 in 5 then go on to have either recurrent
disease or present de novo with symptoms of congestive
cardiac failure. The characteristic feature of juvenile or
adult onset cardiomyopathy is diffuse interstitial and
coarse replacement myocardial fibrosis on post-mortem
or using non-invasive cardiovascular magnetic resonance
imaging [34]. Symptoms on presentation include reduced
exercise capacity, breathlessness on exertion, orthopnoea,
ankle swelling, nocturnal cough and wheeze. Reduced ex-
ercise capacity and breathlessness are relatively sensitive
symptoms but lack specificity for heart failure, due to the
frequency of co-existing issues in ALMS, including phys-
ical de-conditioning, obesity and reversible airways dis-
ease. Physical signs are difficult to interpret and lack
sensitivity and specificity, as many with ALMS have no ab-
normal signs, particularly when the degree of heart failure
is mild. Tachycardia lacks sensitivity and blood pressure is
often normal or patients are treated for hypertension [35].
Likewise, oedema is more common in those who are im-
mobile or obese, while crepitations in the lung fields may
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of fibrosis rather than heart failure. Signs such as elevated
jugular venous pressure and displacement of the apex beat
are more specific but are much harder to elicit and have
poor reproducibility [36].How is cardiovascular disease diagnosed in Alström
syndrome?
Statement # 9: Although an abnormal electrocardiogram
may increase the likelihood of cardiovascular disease in
individuals with ALMS, and elevated plasma concentra-
tions of natriuretic peptides can be used as an initial
diagnostic test, transthoracic echocardiography is the
most useful and widely available test for diagnosis, esti-
mating prognosis and monitoring response to treatment.
 Level of evidence: C
 Strength of recommendation: 1
 Experts’ opinion: completely agree (75%), mostly
agree (17%), partially agree (8%), mostly disagree
(0%) and completely disagree (0%)
Plasma concentrations of natriuretic peptides can be a
useful initial test for diagnosis of CHF in patients with
ALMS, since those with normal levels are unlikely to
have CHF. Their use is mainly in excluding disease,
since there are other causes for elevated levels, including
advancing age > 50 years, pulmonary hypertension and
renal dysfunction, while obesity may lower levels [37].
Abnormalities on the 12-lead electrocardiogram occur
in a third of patients with ALMS but changes are non-
specific and include axis deviation, criteria for left ventricu-
lar hypertrophy, poor R wave progression and non-specific
ST changes [35]. It was initially suggested that transthoracic
echocardiography commonly identified abnormalities in
structure and function in infants and children with ALMS,
with a high frequency of left ventricular dilatation, globally
impaired left ventricular ejection fraction without regional
wall motion abnormalities and reduced right ventricular
function [38]. Subsequent studies using echocardiography
and cardiovascular magnetic resonance imaging in larger
populations of subjects have indicated that overt reduction
in ejection fraction may be present in approximately a third
but that ventricular size is commonly normal [35]. Using
gold standard cardiovascular magnetic resonance imaging,
left and right ventricular size is commonly normal in adults,
and mass is within normal range with normal wall thick-
ness [34]. Of interest, sub-clinical left ventricular (LV) dys-
function has been documented on advanced image analysis
with 2D feature tracking and reduction in global longitu-
dinal strain, and there remains a question whether this may
be more common in those who recovered from infantile
cardiomyopathy [39]. It is not known whether reduction inglobal longitudinal strain is predictive of adverse events, as
in the general adult population.
What is the role of myocardial fibrosis in Alström
syndrome?
Statement # 10: There is evidence on post-mortem and
on non-invasive cardiovascular imaging of coarse re-
placement and diffuse interstitial fibrosis in the heart. It
is not known whether this is direct consequence of the ab-
normal ALMS1 protein or a result of the metabolic de-
rangements that are associated with ALMS.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (74%), mostly
agree (13%), partially agree (13%), mostly disagree
(0%) and completely disagree (0%)
Post-mortem evidence in the largest series of cases
presented to date demonstrated myocardial fibrosis in
the hearts of 3 out of 4 patients with cardiomyopathy
and mild fibrosis in the heart of one patient who had no
history of cardiovascular disease [25]. Non-invasive mul-
tiparametric cardiovascular magnetic resonance imaging
demonstrated coarse replacement fibrosis in 5 of 7 adult
patients with Alström syndrome, with a typical pattern
of late gadolinium enhancement within the mid wall of
the left ventricle [40]. While late gadolinium enhance-
ment quantifies coarse replacement fibrosis, it does not
detect diffuse interstitial myocardial fibrosis, which has
been identified in most adult patients using T1 mapping
and extracellular volume quantification [41]. There is
some evidence that fibrosis is progressive, but data are
unclear whether this structural change is causative or a
marker of the development of cardiomyopathy. Data
have suggested that the presence of fibrosis may be
reflected in sub-clinical changes in function measured by
strain [34]. There are currently no effective treatments
known to reverse myocardial fibrosis in ALMS. Fibro-
blast primary cultures obtained from patients with
ALMS up-regulated the expression and production of
collagens displaying a constitutively activated myofibro-
blast phenotype even if they do not derive from a fi-
brotic lesion [42]. It is not clearly demonstrated if the
multi-organ fibrosis could be a direct consequence of
ALMS1 dysfunction or a result of secondary metabolic
alterations.
Do patients with ALMS develop coronary artery
disease?
Statement # 11: Occult coronary disease is present in
one third of adult patients with Alström syndrome before
50 years of age but symptomatic disease does not occur in
children and is rare in adults.
 Level of evidence: C
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 Experts’ opinion: completely agree (73%), mostly
agree (18%), partially agree (9%), mostly disagree
(0%) and completely disagree (0%)
Metabolic disturbances are cardinal features of ALMS
and begin in childhood, with effects including rapid
weight gain, disproportionate IR, type 2 diabetes mellitus
(T2DM) and dyslipidaemia. The high prevalence of risk
factors, particularly when combined with the difficulties
in following an active lifestyle imposed by visual and
hearing impairment, increase the likelihood of coronary
artery disease. Despite this, reported cases of symptom-
atic coronary artery disease are uncommon [43] al-
though there is post-mortem evidence on histology of
asymptomatic myocardial infarction [34]. On this basis,
it seems reasonable to follow a strategy of aggressive risk
reduction in patients, noting that previous reports of im-
paired LV function and cardiomyopathy have not ex-
cluded coronary artery disease in a structured manner.
Endocrine and metabolic functions
Empty Sella, hypothyroidism, short stature
Statements # 12: Total or partial empty sella may
present in ALMS and it might represent the morpho-
logical underpinning of endocrine dysfunctions of the pi-
tuitary gland. Hypothyroidism and growth hormone
deficiency are common findings. The majority of children
have a rapid growth, with height above the 50th percent-
ile before puberty but final adult height frequently below
the 5th percentile.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (33%), mostly
agree (50%), partially agree (17%), mostly disagree
(0%) and completely disagree (0%).
Hypothyroidism (range 11–36%) and sub-clinical
hypothyroidism have been reported in patients with
ALMS [19, 25, 44, 45]. Hypothyroidism may be primary
or secondary and it is related to autoimmunity in 20% of
cases [45].
Up to 50% normal weight patients with ALMS have an
inadequate GH reserve and may be functionally GH de-
ficient [19, 44, 46]. Few patients have been treated with
rhGH [46, 47]. After 1 year of rhGH treatment, body fat
mass, fat infiltration in the liver, and serum lipid profiles
had all decreased; insulin sensitivity and acanthosis
nigricans improved [47]. Short stature may be at least
partially influenced by impairment of the IGF-1 axis [45,
48] or pituitary fibrosis [44]. Patients with ALMS and
controls have similar arm span/height ratios and sitting/standing height ratios [45]. A skeletal age of 1–3 years in
advance of chronological age has been reported in chil-
dren [19, 25, 44]. Thoracic and lumbar scoliosis, ky-
phosis, or lordosis is present in 68% of patients with
ALMS [25].
In a cohort of 38 patients a diagnosis of central adrenal
insufficiency was found in a single case [45]. No alter-
ations of prolactin have been reported to date. Central dia-
betes insipidus was reported in a single case [49].
Male hypogonadism and female hyperandrogenism
Statement # 13: Male hypogonadism and female hyper-
androgenism are common findings in ALMS. Microphal-
lus, undescended testes, hypospadias, small testes and
gynecomastia can be present in men. Women can show
hirsutism, alopecia, oligomenorrhea or amenorrhea, poly-
cystic ovaries, high testosterone levels, abnormal breast
development, precocious puberty and endometriosis.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (71%), mostly
agree (29%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%).
Hypergonadotropic and hypogonadotropic hypogonad-
ism are common in males [19, 25, 44, 45]. Histopatho-
logic findings showed testicular atrophy with obliterating
fibrosis of seminiferous tubules [25]. Males are unlikely
to be fertile. Erectile dysfunction and sexual drive have
not been thoroughly investigated. Testosterone replace-
ment therapy should be offered as per the national
guidelines.
Women present normal external genitalia, uterus, and
fallopian tubes; however, menstruation is often scant,
sporadic, or irregular. Histopathological studies showed
extensive fibrosis of the ovary and devoid of oocytes, fol-
licles, and corpora lutea [25]. A relatively high frequency
of ovarian cysts is reported, which may be associated
with obesity and hyperinsulinemia. Female fertility is un-
likely and no patients have reproduced so far. Metfor-
min, estrogens, progestins, or their combination might
be helpful to normalise menstrual irregularities.
Childhood obesity
Statement # 14: Childhood obesity occurs in most of pa-
tients with ALMS. Although birth weight is within the
reference range, rapid weight gain can be observed within
2 to 36 months. Waist circumference, Body Mass Index
(BMI) and percent fat mass tend to decrease with age
after adulthood.
 Level of evidence: B
 Strength of recommendation: 1
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agree (50%), partially agree (7%), mostly disagree
(0%) and completely disagree (0%)
Obesity is one of the cardinal features of ALMS [16, 50,
51]. ALMS is characterized by fat accumulation in sub-
cutaneous instead of visceral regions [52]. Adipose tissue
(AT) histology showed disordered pro-inflammatory and
fibrotic gene expression profiles [53]. Adipocytes of sub-
cutaneous and visceral AT were larger than controls in
mouse model [54] and human specimens of patients with
ALMS [53].
Leptin levels are elevated and correlate with body
weight [48]. However, mild elevations in leptin levels
normalized to BMI, suggest leptin resistance [55]. Rest-
ing energy expenditure is comparable with controls but
the hyperphagia score may be higher, suggesting that
higher intake rather than the lower metabolic rate is
probably the primary driver for obesity in ALMS [45]. In
the mouse model fat Aussie (foz/foz), hyperphagia was
observed before weight gain [56].
Insulin resistance, type 2 diabetes and dyslipidaemia
Statement # 15: Almost all individuals with ALMS are
prone to insulin resistance (IR). The severity and degree
of complications of IR increase with age and body habitus
and yet disproportionate to BMI. Patients with ALMS
have a 10-fold greater prevalence of metabolic syndrome;
most patients during their lifetime develop type II dia-
betes and moderate to severe dyslipidaemia.
 Level of evidence: A
 Strength of recommendation: 1
 Experts’ opinion: completely agree (93%), mostly
agree (0%), partially agree (7%), mostly disagree (0%)
and completely disagree (0%)
In a large cohort of patients with ALMS, hyperinsuli-
nemia usually developed between ages 18 months and 4
years [25]. Type 2 diabetes mellitus (T2DM) can be diag-
nosed as early as age 5 years, with a median age at onset
of 16 years [25]. Eighty-two percent of patients older
than 16 years were diabetic [25]. The severity of IR is
more than 10 times that of BMI-matched patients with
obesity [45].
In the ALMS1 GT/GT and foz/foz, mouse models,
hyperinsulinemia develops early and pancreatic islets
show beta cell proliferation, thus suggesting that both IR
and increased insulin secretion might contribute to glu-
cose intolerance [10, 56]. Using zebrafish models, loss of
Alms1, resulted in a significant decrease in β-cell pro-
duction and under prolonged exposure to high glucose
conditions, β-cells were unable to continually expand as
a result of decreased proliferation and increased celldeath [57, 58]. The knockdown of Alms1 resulted in ex-
cess secreted insulin and cellular transport, especially in
insulin-related pathways, prior to the onset of adipogen-
esis. These findings support a role for Alms1 in regulat-
ing secretion and membrane depolarization in β-cells
[58]. In addition, a role for ALMS1 in glucose homeosta-
sis and GLUT4 translocation in adipose tissue of ALMS1
GT/GT mouse model was shown [54]. In patients with
ALMS, ectopic fat deposition in the liver and potentially
skeletal muscle could play a key role in the IR develop-
ment [45].
Most patients have moderate to severe hypertriglyc-
eridemia [range 200-1000 mg/dL (2.26–11.29 mmol/L)],
with normal total cholesterol and low HDL cholesterol
levels [25, 45, 59, 60]. ALMS patients with triglyceride
levels greater than 1000mg/dL (11.3 mmol/L) are prone
to develop acute pancreatitis [25]. In addition, low levels
of apolipoprotein A1 [60] and HDL [45] were reported.
Unexpectedly, LDL-cholesterol was lower in patients
with ALMS compared with BMI-matched controls [45].
Non-alcoholic fatty liver disease
Statement # 16: Non-alcoholic fatty liver disease (NAFL
D) is common in ALMS with a high tendency to progress
to non-alcoholic steatohepatitis (NASH) and fibrosis dis-
proportionate to age, BMI and duration of T2DM.
Plasma concentration of liver enzymes is often elevated
starting in early childhood. In some affected individuals,
liver disease progresses to cirrhosis and hepatic failure in
the second to third decade. Portal hypertension associ-
ated with splenomegaly, oesophageal varices, ascites, and
hepatic encephalopathy may occur.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (93%), mostly
agree (7%), partially agree (0%), mostly disagree (0%)
and completely disagree (0%)
Advanced cases of NAFLD were reported in the UK
adult cohort of 30 patients with ALMS and T2DM [53].
Advanced cirrhosis of the liver can occur in teenage
years and in the absence of severe obesity, diabetes or al-
cohol excess. Conversely some obese severely insulin re-
sistant and diabetic ALMS persons have been found to
have normal livers at autopsy. Liver biopsies and post-
mortem examination have revealed varying degrees of
NASH, liver fibrosis, cirrhosis, and more nonspecific
chronic active hepatitis with lymphocytic infiltration and
patchy necrosis [25, 61]. Early stages of NASH (inflam-
mation, hepatocyte ballooning, steatosis) can remit and
relapse with significant improvements in weight loss (in
the obese cases), exercise tolerance, IR and blood sugar
[62]. More research is needed to determine whether ad-
vanced cirrhosis as opposed to steatohepatitis is driven
Tahani et al. Orphanet Journal of Rare Diseases          (2020) 15:253 Page 9 of 22primarily by direct genetic effects on the liver rather
than secondary effects of the syndrome such as degree
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Respiratory involvement
Do ALMS patients have respiratory problems?
Statement # 17: There is a higher prevalence of upper
and lower respiratory tract infection in ALMS. Children
with ALMS have an increased incidence of respiratory in-
fections, which seems to reduce during adulthood. Con-
ventional Lung Function testing is often difficult due to
dual sensory loss and problems with coordinating of deep
inspiration and forced expiration. When performed,
many cases show a restrictive pattern, often with a main-
tained transfer coefficient of the lung for carbon monox-
ide (KCO).
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (69%), mostly
agree (31%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%)
Recurrent otitis media is very common at all ages and
tympanostomy tubes are often placed in children with
chronic otitis media to prevent recurrence and compli-
cations. Boerwinkle et al. reported episodes of bronchitis,
pneumonia and sinusitis in more than half of 38 patients
with Alström syndrome [63].
Restrictive lung disease is frequently described and it
can be due to extrapulmonary restriction from obesity
or less commonly kyphoscoliosis, sometimes in combin-
ation with alveolar and interstitial fibrosis. In case of
severe and progressive scoliosis, surgery may be consid-
ered. In less severe cases or if the risks of surgery are
considered too high, braces could be an alternative.
Histopathological studies have shown early morpho-
logical changes indicating an inflammatory process in
the small airways [27] and post mortem studies have de-
scribed alveolar and interstitial fibrosis.
There is a reported increased susceptibility of sudden
and severe hypoxaemia during or following anaesthesia
or surgery [64]. The underlying mechanisms for severe
hypoxia is unknown but could be related to cytokine
storm triggered by host immune response.
Renal and urological complications
Renal disease
Statement # 18: Chronic kidney disease is common,
slowly progressive, and highly variable. Onset can be in
mid-childhood through adulthood. End-stage renal dis-
ease can occur as early as the mid- to late teens. Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (81%), mostly
agree (19%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%)
Renal ultrasonography and Magnetic Resonance Im-
aging (MRI) may reveal abnormalities. The most com-
mon ultrasonography finding is renal parenchymal
hyperechogenicity often limited to the medulla. Renal
cysts are identified in a small number of patients [65, 66].
Renal biopsy often shows interstitial fibrosis, glomerular
hyalinosis, and tubular atrophy but absence of histopatho-
logic features of diabetic or reflux nephropathy [25, 65]. In
addition, glomerular function in Alström syndrome does
not show significant association with T2DM, hyperlipid-
emia, cardiomyopathy, or hypertension, suggesting that
kidney disease may be the primary manifestation of the
syndrome. Diabetes, hypertension and hyperuricemia may
have an additive effect on the progression of renal disease.
Microalbuminuria is common but not overt proteinuria
despite the presence of T2DM. Obstructive uropathy is
rare. It is reported in the literature a case of successful kid-
ney transplant because of chronic renal failure in a 42-
year old man with ALMS [67].Dysuria
Statement # 19: Up to 50% of patients with ALMS have
reported dysuria and or long periods without voiding
urine. These symptoms have been attributed to detrusor-
urethral dys-synergia (lack of coordination of bladder
and urethral muscle activity). More severe problems ap-
pear to occur in females in their late teens. Lower ab-
dominal and perineal pain is common and may relate to
bladder spasm.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (69%), mostly
agree (23%), partially agree (8%), mostly disagree
(0%) and completely disagree (0%)
There has been no systematic study of urological func-
tion in ALMS. Manifestations include urinary frequency,
incontinence, and symptoms associated with recurrent
infections [31, 68]. More severe manifestations are rare
(< 2%) and include worsening urinary incontinence or
retention; these symptoms may alternate.
A few case reports describe severe detrusor urethral
dysfunction in female patients with ALMS. The detrusor
spasm interfered with all aspects of daily living and was
partially or not responsive to antispasmodics or self-
catheterisation. In all cases, urinary diversion procedure
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Gastrointestinal dysfunction
Statement # 20: General gastrointestinal disturbances
such as epigastric pain and gastro- esophageal reflux dis-
ease are common. Rarely, spontaneous caecal volvulus
can occur.
 Level of evidence: C
 Strength of recommendation: 1
 Experts’ opinion: completely agree (64%), mostly
agree (9%), partially agree (18%), mostly disagree
(9%) and completely disagree (0%)
Recurrent symptoms of epigastric pain, nausea, regur-
gitation of food and heartburn were found in 19% of 178
patients with ALMS compared with 8% of children with-
out the syndrome [69]. There have been no reports of
systematic investigation of gastro-oesophageal reflux in
the syndrome. Two genetically confirmed cases have
been investigated and treated for severe reflux which
had interfered with quality of life [15]. One proceeded to
successful gastric plication.
Caecal volvulus has been reported in a sibling pair
with genetically confirmed ALMS [70]. No other cases
of small or large bowel volvulus have been reported. It is
possible that a co-inherited anatomical deformity of the
bowel underlay the volvulus rather than the presence of
ALMS.
Developmental and neurological observations
Statement # 21: Developmental milestones can be de-
layed in ALMS individuals, most commonly in gross and
fine motor skills. Learning disability and mixed
receptive-expressive language delays are also reported.
Cognitive impairment (IQ < 70) is very rare. The ages at
which children first sit, walk, and organise phrases of at
least 2 words can be used as psychomotor developmental
milestones during childhood.
 Level of evidence: C
 Strength of recommendation: 1
 Experts’ opinion: completely agree (54%), mostly
agree (33%), partially agree (13%), mostly disagree
(0%) and completely disagree (0%).
The most comprehensive analysis of psychosocial out-
comes in the syndrome was led by Marshall et al. and
reported in the review defining the phenotype in 182
cases of the syndrome [25]. Mentation and neurobehav-
ioral traits were estimated on the level of school and social
performance and interviews with parents. Intelligence
tests included the Wechsler Adult Intelligence Scale–Revised, the Bayley Scales of Infant Development, Birth to
Three Test of Language and Learning Development, Be-
haviour Assessment System for Children, and the Haptic
Intelligence Scale for the Adult Blind. Developmental
milestones were delayed in 39 males and 35 females
(46%). Autistic-spectrum behavioural abnormalities were
common.Do patients with Alström syndrome develop
neurological disease?
Statement # 22: Neurological manifestations such as
seizure and hyporeflexia can occur up to 20% patients.
Subtle brain volume and intensity changes were noted in
neuroimaging assessments.
 Level of evidence: C
 Strength of recommendation: 1
 Experts’ opinion: completely agree (64%), mostly
agree (22%), partially agree (14%), mostly disagree
(0%) and completely disagree (0%).
Hyporeflexia was observed in 20% of patients (age
range, 9 months to 41 years). 12% of these patients had
frequent absence seizures. Birth complications included
neonatal hypoxia and hypotonia. Excessive startle, partial
unilateral paralysis, unexplained joint or muscle pain
and muscle dystonia were also reported. 16% had gener-
alized sleep disturbances (age range, 3–41 years) [25].
Other smaller studies have shown wide heterogeneity in
theory of mind performance. For example, with many
patients with ALMS performing as well as controls, but
those with earlier visual loss showing impaired responses
to abstract questioning [71].
One study has compared patients with ALMS with
controls using conventional MRI, Voxel-Based Morph-
ometry (VBM) and Diffusion Tensor Imaging (DTI). In
contrast with patients under investigation for epilepsy,
matched for age and gender, there were early vascular-
like lesions, grey and white matter atrophy, mostly in-
volving the posterior regions, and diffuse supratentorial
white matter derangement. These ALMS related cerebral
structural change might underlie behavioural and devel-
opmental problems in a minority of patients [72].Psychosocial aspects
Statement # 23: The effects of complete visual loss or
realisation can result in severe anxiety and depression
often in late adolescence. Anxiety and depression, learn-
ing challenges and barriers to engagement in society are
influenced by age at diagnosis, the cultural setting in
which the child with ALMS grows up, life limiting com-
plications, and the ability to respond to the challenge of
visual loss.
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 Strength of recommendation: 2
 Experts’ opinion: completely agree (80%), mostly
agree (20%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%).
Psychological and sociological consequences of the
syndrome have been reviewed by questionnaires and in-
terviews with families. Progress can be compromised by:
lack of aids to low vision, Braille and computer voice
mail; development of deafness and lack of good audi-
ology support; the reaction especially in adolescence to
an understanding of the severity of the condition par-
ticularly blindness. If early education, treatment and pre-
vention of complications and integration in society can
be offered from infancy, there is a much greater likeli-
hood of good mental and physical wellbeing.
The immense relief at finding the cause of visual im-
pairment and obesity is coupled with consternation and
fear at the realization of the serious, incurable, and pro-
gressive nature of ALMS. Severe neuronal deafness can
have devastating effects of withdrawal and depression if
adequate digital hearing aids are not available in a time
sensitive manner. Moreover, episodes of screaming, ag-
gression, and withdrawal from engagement with family
have been described in an adolescent with sudden
complete loss of vision.
Diagnosis and differential diagnosis of Alström
syndrome
The symptoms and signs of ALMS vary with the age at
diagnosis. Visual impairment is the earliest and most
consistent observation in all patients starting from few
weeks of life. There are numerous conditions raising the
suspicion of ALMS and other age appropriate diseases
should also be excluded.
Statement # 24: In the first few years of life, history
of visual impairments and/or cardiomyopathy/heart
failure should raise the possibility of ALMS. The
differential diagnosis includes other causes of retinal
dystrophies such as Leber’s Congenital Amaurosis,
Achromatopsia, Bardet-Biedl or Early Onset Cone rod
dystrophy.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (75%), mostly
agree (25%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%).
Night blindness is not a common feature in ALMS as
opposed to other forms of inherited syndromic retinal
dystrophies, mostly nystagmus and photophobia are theleading signs. The clinical context (obesity, cardiomyop-
athy) and finally molecular testing will categorise defini-
tively the precise type of syndromic retinal dystrophy as
ALMS. Since clinical diagnosis could overlap with other
conditions, targeted gene panels that includes ALMS1
gene should be employed, in order to exclude other clin-
ical diagnosis in one molecular test. Targeted panel for
ciliopathies, retinal diseases, cardiomyopathy or even
obesity should include ALMS1 gene. As children age, the
syndromic features of ALMS become more apparent
with metabolic, hearing, cardiac and renal related mani-
festations coming to prominence.
Statement # 25: Once ALMS is suspected based on age
appropriate syndromic features, diagnosis can be con-
firmed by identification of biallelic pathogenic variants
in ALMS1 gene.
 Level of evidence: A
 Strength of recommendation: 1
 Experts’ opinion: completely agree (75%), mostly
agree (0%), partially agree (25%), mostly disagree
(0%) and completely disagree (0%).
There is no biochemical, histological or imaging test
to confirm the diagnosis of ALMS and molecular genetic
study is the only option in confirming the diagnosis. To
overcome the challenges of identifying both biallelic
pathogenic variants in ALMS1 gene, diagnostic criteria
based on cardinal clinical features and family history
were proposed [25]. However, given the overlap of clin-
ical features with other syndromic ciliopathy/retinopathy
and the advance in molecular genetic study attempt
should be made to identify two pathogenic variants to
confirm or refute the diagnosis of ALMS.
The classical molecular approach is to sequence the
hotspot exons (8, 10 and 16) and if no mutation is de-
tected, the entire coding sequence is analysed. Now-
adays, the implementation of the new sequencing
technologies is replacing this classical approach. Next
generation sequencing-based gene panels for retinal dis-
eases, syndromic ciliopathies and syndromic obesity or
whole-exome sequencing (WES) of the proband could
be performed, for the entire exon content. Checking the
coverage and length of reads of the reaction is compul-
sory in order to produce a good detection rate. If no, or
only one, pathogenic variant is detected, other strategies
should be taken. Multi ligation probe assay (MLPA)
could potentially be used to detect large deletion or in-
sertions in regions not included in the exonic analysis.
Whole genomic sequencing (WGS) provides a full
spectrum of genetic variations, not only point mutations
and small insertions/deletions but also larger copy num-
ber variations and variants that is located in noncoding
Table 3 Multidisciplinary assessment of patients with ALMS
Discipline Features of ALMS for which
this discipline may be of
assistance
Initial Assessment Follow up Reference
Primary care
physician
Assist with general medical
care; coordinate specialists;
provide support for family
First referral at the time of
diagnosis.





Diagnosis of ALMS and
exclusion of other disorders
in the differential diagnosis;
provide counselling for
families as to recurrence risk
and option for prenatal
diagnosis if desired.
First referral prenatal or
during childhood. Initial
assessment: detection of two
ALMS1 biallelic variations in
the proband. Then,
assessment of family
segregation to establish the
parental alleles.






First referral usually before





(performed according to the
age of patient and level of
participation).
Annually [73]
ENT specialist Progressive bilateral
sensorineural hearing loss.




evaluation of both ears.
Annually [33]




First referral possibly before




older children and adult,
include CMR.
ECG - yearly
TTE – yearly or as per
clinical need
CMR every 3–5 years
[35, 40]
Pulmonologist Assess for pulmonary fibrosis;
restrictive lung disease;
pulmonary hypertension.




Function test (cPFT) and
Chest X-ray. HRCT Thorax in
cases of unexplained cough
or breathlessness.
cPFT – yearly





Assess and treatment of
metabolic complications
(obesity, insulin-resistance,
type II diabetes, non-
alcoholic fatty liver disease,
dyslipidaemia) and endocrine
disorders (hypothyroidism,








2. Thyroid Function Test
(TFT), Pituitary and sexual
hormones
3. Blood glucose, HbA1c and
lipid profile.
Every 6–12 months in
children, then yearly
Yearly
Every 6–12 months or as
per clinical need
[13, 25, 45, 48]
Gastroenterologist/
hepatologist





First referral: from childhood
to adulthood
Initial assessment: Liver
function tests, platelet count,
liver ultrasound, transient
elastography and ELF test.
Upper gastrointestinal
endoscopy (EGD) in case of
cirrhosis
Yearly or as per clinical
need
Liver ultrasound yearly
or as per clinical need.
[53]
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Table 3 Multidisciplinary assessment of patients with ALMS (Continued)
Discipline Features of ALMS for which
this discipline may be of
assistance
Initial Assessment Follow up Reference
Nephrologists Assess for progressive renal
dysfunction, Chronic Kidney
Disease.






Yearly or as per clinical
need
[65]













As per clinical need [27, 72]
Anaesthesiologist Assess for anaesthetic risk. First referral as per clinical
need.






Support to personal and
group activity.
First referral: from mid-
childhood to adulthood
Initial assessment includes:




Physioterapist Aerobic physical exercise. First referral: from childhood
to adulthood, as per clinical
need.
Initial assessment: static and
dynamic physical
examination.




























Yearly or as required [76]
Social worker Support of patients and
families living with
disabilities, who require
enhanced resources in the
community
First referral: from childhood
to adulthood
As required Expert opinion
Patients’ Association Support to patients and their
families
Facilitate clinic and research
First referral at the time of
diagnosis
As required [77]
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ALMS1 gene have been described once, several popula-
tions showed a founder effect like the UK or Turkish
population [3].
Management
ALMS is not yet curable but is a treatable condition. Opti-
mal disease management requires a multi-disciplinary,
multi-professional team (MDT) based in a specialist
centre, closely liaising with community care providers
(Table 3). The mainstay of therapy is addressing theexisting/impending complications and symptom manage-
ment. Van Groenendael et al. [77] undertook a cross-
sectional study of UK patients with ALMS and their
carers. They showed that patients who have access to a
highly specialised clinical service, reported high levels of
satisfaction in their care. Patient treatment compliance
and clinic attendance was better in a multidisciplinary
clinic compared to the usual standard of care. This was as-
sociated with a significantly improved quality of life. In
particular it is important to underline the role of Patients’
Associations in giving information and contacts to resolve
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and families creating opportunities to enjoy life.
Statement # 26: Patients with ALMS exhibit progres-
sive multisystem disease manifestations and benefit from
multidisciplinary follow up from physicians and allied
health care professionals with experience in caring for
ALMS patients in a one stop clinic set up. Wherever pos-
sible, individuals diagnosed with ALMS should be re-
ferred to a centre with expertise in the care of this
condition.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (94%), mostly
agree (6%), partially agree (0%), mostly disagree (0%)
and completely disagree (0%).
Depending on the country’s health care service setup,
level of expertise and patients need, a MDT can be
formed to enable ALMS patients to receive a collabora-
tive management plan from a wide range of experts in
an integrated manner. The MDT should have a Care
Coordinator assigned to the patient serving as a primary
contact point to the rest of the team. Specialists in the
different disciplines have to discuss and integrate infor-
mation and management as much as possible. Treat-
ment goals are defined and agreed with the patient and
their family and regularly reviewed as required. The
MDT should aim to work together in a “one stop” clinic
set up in integrating investigations and clinic appoint-
ments. The MDT will also benefit from a post clinic
meeting in forming a consolidating care plan in a coor-
dinated manner.What optimal therapy should be considered for a patient
with ALMS?
The following functional assessments should take place
at the time of diagnosis or symptom onset and at regular
intervals thereafter for optimal symptom control and
functional capacity.Growth and development, eyesight and hearing
Growth and development
Statement # 27: The growth of children with ALMS
(height, weight, head & waist circumference) should be
assessed at regular intervals (not less than 6 monthly)
using age appropriate instruments by their primary
health care provider. In addition, adult patients should
undergo a careful assessment and change in their an-
thropometric measurements including BMI, body fat
composition and waist circumference. Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (75%), mostly
agree (19%), partially agree (6%), mostly disagree
(0%) and completely disagree (0%).Eyesight
Statement # 28: Individuals with ALMS should undergo
a comprehensive eye assessment at the time of diagnosis
and thereafter on regular interval. Visual loss occurs with
age in all individuals with ALMS and early planning
should be in place in the use of Braille, computing and
adaptive living skills while vision is still present.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (94%), mostly
agree (6%), partially agree (0%), mostly disagree (0%)
and completely disagree (0%).
A yearly ophthalmic examination by an experienced
ophthalmologist is recommended and then by a centre
that has expertise in retinal dystrophies, dedicated to
monitor the ophthalmic status including [31, 77]: best
visual acuity or low vision evaluation; refraction; slit
lamp examination to detect cataracts; fundus examin-
ation; OCT FAF and ERG if possible (Table 2).
In caring for their visual impairments treatment goals
and challenges should be discussed with the patient at
the outset and as the disease progress. Symptomatic
therapies include:
1) Full refraction glasses should be prescribed as long
as some retinal function is detected and residual
vision is present. Red-orange tinted filters have
proven to be very useful to mitigate photophobia.
2) Detection of cataract (mostly subcapsular) can lead
to a surgical procedure (lens removal with
implantation) usually in the second or third decade.
This can improve visual symptoms (especially
photophobia) although the benefits on vision may
be limited and tempered by the state of the
underlying retinal degeneration.
3) Rehabilitation for gradually deteriorating vision
must be carried out by an expert team with early
intervention with the use of low vision aids,
magnifiers, mobility aids (white cane, guide dogs) as
well as Braille learning. In addition, Smartphone,
tablets and the use of multiple apps are currently
available for use by severely visually impaired
persons. Voice activated technologies are of major
help. The goal is to achieve autonomy and
independence.
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reached the stage of clinical trial (due to the size of
ALMS1 gene). Retinal implants have been advocated in
late stage retinal dystrophies but we are not aware of
any patient with ALMS having benefited from these
devices.
Hearing
Statement # 29: People with ALMS should undergo a
hearing assessment at the time of diagnosis and there-
after annually. When appropriate, patients should be of-
fered hearing devices to improve general communication.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (88%), mostly
agree (12%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%).
Hearing problems are a common manifestation that
starts during childhood as a progressive sensorial deaf-
ness [25, 26]. In addition to the neurosensorial dysfunc-
tion, more than 42% of the children present with otitis
media (glue ear) and have to undergo myringotomy.
Chronic recurrent otitis media is commonly reported
even in young adults [63]. This can add a conductive
component to the deafness. Patient should be followed
by age appropriate air bone conduction pure tone thresh-
olds, speech thresholds, ability to word recognition with
diagnostic audiometers, tympanometry, otologic examin-
ation and microscopic examination of both ears.
Hearings aids are very useful and have to be regularly
monitored and adapted. Cochlear implantation has been
reported and should be considered as it may have an
excellent functional outcome [73, 78, 79].
The heart, cardiovascular and respiratory systems in ALMS
Cardiomyopathy
Statement # 30: Cardiovascular disease occurs in the
majority of ALMS patients at some time in their lives.
Cardiovascular assessment should be performed at the
time of diagnosis and regularly thereafter. Standard
heart failure therapy should be used in patients with
heart failure and reduced ejection fraction, including
angiotensin converting enzyme inhibition (ACEI) and
beta-blocker titrated up to the maximum tolerated
evidence-based dose, with a mineralocorticoid antagonist
added thereafter. Consideration should be given to re-
placement of the ACEI with sacubitril valsartan in adults
with an ejection fraction below 35% and persisting symp-
toms. Further consideration should be given to the
addition of ivabradine if the heart rate is > 72/min des-
pite optimisation, and cardiac resynchronisation therapyin those with QRS duration > 130 ms and persistent
symptoms. Diuretics are recommended to reduce symp-
toms and signs of CHF.
 Level of evidence: A
 Strength of recommendation: 1
 Experts’ opinion: completely agree (92%), mostly
agree (8%), partially agree (0%), mostly disagree (0%)
and completely disagree (0%).
The following cardiac evaluations should be assessed
at presentation and thereafter at regular intervals:
a) Standard 12-lead electrocardiograms (ECGs) –
yearly
b) Transthoracic echocardiograms – yearly or as per
clinical need
c) Cardiac magnetic resonance (CMR) imaging for
older children and adult at baseline and 3 to 5
yearly intervals.
Statement # 31: Although in the general population of
patients with HF, a high proportion of deaths occur sud-
denly and unexpectedly due to electrical disturbance, the
risk of arrhythmia is not well defined. Although there
have been concerns raised regarding the efficacy of im-
plantable cardioverter-defibrillators (ICD) in non-
ischaemic cardiomyopathy, current standard indications
should be followed, including:
a) Implantation of an ICD in those recovering from
aborted sudden cardiac death or proven ventricular
tachyarrhythmia causing haemodynamic instability
in those with survival expected > 1 year;
b) Implantation of an ICD in those with advanced
symptoms and reduced ejection fraction < 35%
despite optimal medical therapy with survival
expected > 1 year
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (66%), mostly
agree (17%), partially agree (17%), mostly disagree
(0%) and completely disagree (0%).
Statement # 32: In those presenting with acute HF
who fail to respond to standard medical therapy, consid-
eration should be given to acute mechanical circulatory
support. At present, these are used in those who have
end-stage heart failure but are eligible for heart trans-
plantation as a bridge to transplantation. Cardiac trans-
plantation is an option in ALMS, although mechanical
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native destination therapy in patients.
 Level of evidence: C
 Strength of recommendation: 2
 Experts’ opinion: completely agree (50%), mostly
agree (42%), partially agree (8%), mostly disagree
(0%) and completely disagree (0%).Cardiovascular risk
Statement # 33: Adult patients with ALMS are at an in-
creased risk of premature ischemic cardiovascular disease
due to their extreme IR and associated metabolic compli-
cations such as dyslipidaemia, hypertension, T2DM and
NASH. Their cardiovascular risk should be modified
using the current national guidelines for secondary
prevention.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (69%), mostly
agree (31%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%).Respiratory system
Statement # 34: Respiratory assessment should be per-
formed at diagnosis and regularly after if there are any
respiratory symptoms. A chest X-ray would be the initial
investigation of choice. A restrictive pattern on Lung
Function testing is often due to extrapulmonary restric-
tion. Many patients will unfortunately find it difficult to
do conventional Lung Function Testing. A low threshold
for HRCT Thorax is advisable in cases of unexplained
cough or breathlessness to rule out fibrotic lung disease.
 Level of evidence: C
 Strength of recommendation: 2
 Experts’ opinion: completely agree (70%), mostly
agree (15%), partially agree (15%), mostly disagree
(0%) and completely disagree (0%).
Statement # 35: Lower respiratory tract infection in
ALMS patients can sometimes progress rapidly and strat-
egies in prevention such as a regular winter flu jab and
pneumonia vaccine should be sought proactively. Patients
with ALMS who contracted moderate to severe pneumo-
nia should be treated aggressively in an intensive care set
up with a particular attention of supporting their cardio-
respiratory and renal functions.
 Level of evidence: B
 Strength of recommendation: 2 Experts’ opinion: completely agree (79%), mostly
agree (14%), partially agree (7%), mostly disagree
(0%) and completely disagree (0%).
Statement # 36: Patients with ALMS are prone to hyp-
oxic episodes during minor surgical procedures, anaesthe-
sia or severe infection. Care must be taken during
sedation for surgical procedures. Extubation post-surgery
should take place carefully after adequate oxygenation
with close monitoring of oxygenation and cardiac status
until 24 h post full recovery.
 Level of evidence: C
 Strength of recommendation: 2
 Experts’ opinion: completely agree (84%), mostly
agree (8%), partially agree (8%), mostly disagree (0%)
and completely disagree (0%).
Endocrine and metabolism
Obesity and insulin resistance
Statement # 37: ALMS patients should regularly be
screened for metabolic complications such as T2DM, dys-
lipidaemia and hypertension. A structured and persona-
lised lifestyle programme should be encouraged and
supported to promote healthy eating, regular exercise
and healthy weight attainment and maintenance.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (88%), mostly
agree (12%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%).
Almost all individuals with ALMS are prone to obesity
and IR. The severity and degree of complications of IR
increase with age and body habitus. Metabolic complica-
tions improve with weight loss and a structured and per-
sonalised lifestyle programme should be encouraged and
supported [13, 45, 60, 62, 80].
Treatment for T2DM and obesity in ALMS include
diet, weight management, and lifestyle modification
counselling, provided by a physician and dietician [3, 27,
52, 62, 81]. Regular aerobic exercise with adaptations for
the blind are recommended to control both obesity and
diabetes [3, 27, 31, 62]. IR / T2DM should be treated as
in the general population. Younger patients rarely re-
quire insulin, but some patients require long term insu-
lin in very-high doses. Many patients with ALMS
respond to insulin-sensitizing agents such as metformin
and/or thiazolidinediones (TZDs) and/or dipeptidyl pep-
tidase 4 (DPP4) inhibitors [31, 52, 62]. Sodium-Glucose
Transport Protein 2 inhibitor such as empaglifozin,
canaglifozin has been shown to benefit diabetic patient
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and therefore all adult ALMS patient should be offered
unless contraindicated. In case of compelling need to
promote weight loss consider a Glucagon-like Peptide 1
receptor agonist.
Treatment of hypertriglyceridemia must include good
metabolic control. Some patients with severe hypertri-
glyceridemia responded to low-fat diet combined with
statins and nicotinic acid [31, 81]. Other medications, es-
pecially for severe hypertriglyceridemia, include omega-3
fatty acids and fibrates.
A clinical trial using MC4R agonist, setmelanotide, in
patients with ALMS is currently underway in treating
hyperphagia related weight gain.NAFLD
Statement # 38: Advanced NAFLD is common in adult
patients and needs careful monitoring (yearly) using
liver function tests, platelet count, liver ultrasound
and non-invasive tests of liver fibrosis, namely transi-
ent elastography (Fibroscan©) and Enhanced Liver Fi-
brosis [ELF] test.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (87%), mostly
agree (13%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%)
Even though data are still emerging, the use of non-
invasive fibrosis tests can enable a safe, repeatable as-
sessment of advanced liver fibrosis and potentially avoid
the need for liver biopsy to assess disease severity. In
cases of cirrhosis, upper gastrointestinal endoscopy
should be performed to assess for evidence of varices
and managed as per liver guidelines (i.e. beta-blockers
and/or variceal banding) [82, 83] and liver ultrasound 6-
monthly to screen for hepatocellular carcinoma. Patients
with complications of advanced liver disease and/or por-
tal hypertension should be evaluated for possible early
liver transplantation [53].Hypothyrodism and hypogonadism
Statement # 39: Hypothyroidism is common in patients
with ALMS and all individuals should have their thyroid
function assessed on a yearly basis and treated
accordingly.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (80%), mostly
agree (20%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%).Statement # 40: As children approach puberty, go-
nadotropin and pituitary hormones should be assessed.
Male hypogonadism in adult is almost universal and
should be treated with testosterone replacement as per
local guidelines
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (79%), mostly
agree (21%), partially agree (0%),mostly disagree
(0%) and completely disagree (0%).
Kidney and bladder dysfunction
Statement # 41: Kidney disease in ALMS is common,
starts early and progresses with age leading to advanced
Chronic Kidney Disease at a young age. Kidney function
must be monitored regularly and refer to nephrologists as
needed. Patients with Advanced Kidney Disease should
be evaluated for possible early kidney transplant.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (80%), mostly
agree (20%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%).
Statement # 42: Individuals with ALMS should have
their history reviewed for symptoms suggestive of neuro-
genic bladder (recurrent urinary tract infection, nocturia,
incomplete evacuation, dribbling) and be referred for
urologic evaluation if symptoms are present.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (92%), mostly
agree (8%), partially agree (0%), mostly disagree (0%)
and completely disagree (0%).
Genetic counselling
Statement # 43: For genetic confirmation of the diagno-
sis, two ALMS1 biallelic variations have to be detected in
the proband. When a pathogenic variant is detected,
family segregation is recommended in order to establish
the parental alleles. As a recessive model of inheritance,
parents are obligate heterozygous carriers of one of the
mutations detected in the proband. Heterozygotes carriers
are asymptomatic and are not at risk of developing the
disorder. Being, both parents, heterozygous carriers, the
likelihood to have an affected child is 25%, having a car-
rier child 50% and being unaffected and not a car-
rier25%. Although it is not a very common mechanism in
ALMS1 gene, de novo mutations should be considered.
In such cases, paternity testing to confirm de novo muta-
tions is highly recommended.
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 Strength of recommendation: 1
 Experts’ opinion: completely agree (72%), mostly
agree (21%), partially agree (7%), mostly disagree
(0%) and completely disagree (0%).
Prenatal diagnosis
Statement # 44: Prenatal diagnosis and pre-
implantation genetic diagnosis is possible when patho-
genic variants have been identified in an affected family
member.
 Level of evidence: A
 Strength of recommendation: 1
 Experts’ opinion: completely agree (80%), mostly
agree (0%), partially agree (20%), mostly disagree
(0%) and completely disagree (0%).
To date, there is no information in the literature about
female pregnancies or male fathering in patients with
ALMS. For women who wish to become pregnant, a
complete sex hormones evaluation should be required.
In men, semen analysis to investigate their fertility
should be suggested.
Mental wellbeing
Statement # 45: Clinicians, caregivers and individuals
with ALMS should be aware that there is an increased
prevalence of behavioural problems and other psychiatric
disorders such as anxiety and depression. There should
be a low threshold for referral to a clinical psychology/be-
havioural therapy team as appropriate, and for the use
of both non-pharmacological and/or pharmacological
treatments.
 Level of evidence: C
 Strength of recommendation: 2
 Experts’ opinion: completely agree (88%), mostly
agree (12%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%).
The psychosocial impact of growing up and living with
a disease leading to deafblindness is devastating. With
support, young adult will either adapt and therefore cope
well, or fail to adapt and struggle. It is even more disab-
ling when hearing start to deteriorate. In addition, the
realisation of the progressive and severe nature of the
disease leads to anxiety, isolation and depression. It is
paramount that patients with ALMS have regular assess-
ment and support as required in order to maintain an
optimal quality of life.
Statement # 46: Highly specialized Care for dual sen-
sory loss should be considered for deaf-blind individualswith ALMS. Children deaf-blind require thoughtful and
unique educational approaches in order to ensure they
have the opportunity to reach their full potential. The as-
sessment of the sensorial impairment is of high import-
ance and will include communication evaluation, social
interactions, emotional wellbeing, mobility, assistive tech-
nology, habitation and rehabilitation potential.
 Level of evidence: C
 Strength of recommendation: 2
 Experts’ opinion: completely agree (88%), mostly
agree (12%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%).
Visual cues in speech perception, speech recognition
and sound localisation and distance evaluation in dual
sensory loss is of particular importance [84]. A literature
meta-analysis has well determined the key findings of
the acquired deaf-blindness that defines the Alström
group (not taking into account other manifestations of
the disease) [75]:
For communication: experiences of changing
communication needs due to progressive sensory loss,
reluctance to admit their hearing impairment with
family, friends, and others;
For mobility: experiences of embarrassment due to
frequent bumping into objects/people; reported feeling
stigmatised to use assistive devices such as canes in
public and lack of mobility instructors;
Functioning in daily life: experiences of more
difficulty in maintaining independence; tend to need
more help from others to remain independent when
impairment worsens; experiences of reduced
independence in shopping, food preparation, reading,
house cleaning, watching television, reading books,
listening to music, and use of technology;
Social interactions: experiences of constant social
isolation in life due to progressive impairments, on
going loss of independence, and lack of the
communities understanding of how to interact with
deafblind people.
Feelings: feelings of worthlessness, loneliness,
emptiness, uncertainty, fear of losing independence,
and concerns about forming relationships, being
rejected by relatives and friends, and constant concern
for the future; feeling depressed and suicidal thoughts
Statement # 47: All active family members should be
involved in full discussion of the implications of the syn-
drome as appropriate for the age of the child. Whether
mainstream or special schooling for the blind is chosen, a
care plan including family nutrition, access to exercise,
and integration in the community should be looked at.
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 Strength of recommendation: 2
 Experts’ opinion: completely agree (94%), mostly
agree (6%), partially agree (0%), mostly disagree (0%)
and completely disagree (0%).
Counselling is vital. One extensive review of the effects
of living with a rare genetic disease on a family and the
individual underlines the demanding nature of these sit-
uations and the need for family support [85]. However,
counselling assessment tools are not always accessible/
appropriate for deafblind people.
Autism – very difficult to diagnose in ALMS patient
due to deafblindness and lack of appropriate assessment
tools to reach a firm diagnosis. Useful information for





Transition from childhood to adult life
Statements # 48: Most young people with ALMS are
expected to reach adulthood with complex medical and
psychosocial needs. The process of transition from paedi-
atric to adult services should begin early and must
include appropriate services in the community to provide
a seamless transition from childhood to adult life. Indi-
viduals with ALMS may benefit from a detailed assess-
ment identifying barriers to independence in particular
the dual sensory loss.
 Level of evidence: B
 Strength of recommendation: 1
 Experts’ opinion: completely agree (88%), mostly
agree (12%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%).
Advance care planning
Statements # 49: Specialist centre care providers, family
physician/paediatrician and local palliative care services
should develop close working links to support individuals
and families with ALMS through the lifespan, including:
a) advanced care planning with regular updating. b)
proper flow of communication and clear information for
patients and their families, c) a designated point of con-
tact for each stage in their care pathway. An individual
identified as being near the end- of-life may benefit from
ongoing access to palliative care services including for
symptom control, respite, psychological and spiritual
support.
 Level of evidence: B Strength of recommendation: 1
 Experts’ opinion: completely agree (82%), mostly
agree (18%), partially agree (0%), mostly disagree
(0%) and completely disagree (0%).
Future area of research
The natural history of ALMS has evolved in the last few
years with a better understanding of the syndrome and
longer survival. However, there are numerous un-
answered questions about the syndrome as follow:
1. What is the best way of confirming ALMS
diagnosis?
2. Why the retinal dystrophy is present in almost all
patients with ALMS? How to treat it?
3. Why do ALMS patient develop cardiomyopathy as
infant? Why and how does it recover?
4. The onset of cardiomyopathy varies from infancy to
adulthood. Does the same mechanism apply?
5. Why are patients with ALMS extremely insulin
resistant disproportioned to their weight?
6. Why does NAFLD in Alström become more
accelerated in progression than the general
population with excess weight?
7. Is accelerated liver fibrosis caused by the metabolic
complications or ALMS1 gene alternation itself?
8. What is the mechanism driving progressive kidney
disease in ALMS?
9. Why is the syndrome heterogeneous in
presentation and disease progression?
10. What is the function and the structure of ALMS1
protein?
11. Is there one or more ALMS1 proteins with different
tissue-specific functions?
12. Is ALMS a ciliopathy?
13. Could it be reasonable to think about proteintype-
phenotype instead of genotype-phenotype correl-
ation in ALMS?
Concluding remarks
These guidelines are the result of an international col-
laboration of experts in the care of patients with ALMS
and the evidence gathered to write these recommenda-
tions are the best evidence available to the experts.
These guidelines address the management of children
and adults affected by ALMS and are intended to facili-
tate optimal care to all ALMS patients worldwide. In
addition, it defines standards of care against which prac-
tice can be audited and best practice can be spread.
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